본문 바로가기

Effectiveness and safety of combined treatment with herbal medicines and palliative chemotherapy for advanced gastric cancer: A systematic review and meta-analysis

문서 유형
연구출판물 · 리뷰논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1KCI Q4
피인용
Web of Science 3Scopus 2KCI 1
FWCI (Scopus)
0.53
JCR IF
JCR 2024 3
ISSN
2213-4220

저자

  1. 김동현제1저자Pusan Natl Univ, Korean Med Hosp, Dept Korean Internal Med, Yangsan, South Korea
  2. Kim, Soo-DamKorea Inst Oriental Med, KM Sci Res Div, Daejeon, South Korea
  3. Jun, Hyeong-JoonKorea Inst Oriental Med, KM Data Div, Daejeon, South Korea
  4. Kwag, Eun-BinDaejeon Univ, Grad Sch Korean Med, Dept Hepatol & Hematol, Daejeon, South Korea
  5. 신상원Pusan Natl Univ, Sch Korean Med, Dept Humanities & Social Med, Yangsan, South Korea
  6. Yoo, Hwa-SeungDaejeon Univ, Seoul Korean Med Hosp, East West Canc Ctr, Seoul, South Korea
  7. 박소정교신저자Pusan Natl Univ, Korean Med Hosp, Dept Korean Internal Med, Yangsan, South Korea

초록

Background: Advanced gastric cancer (AGC) is a leading cause of cancer-related deaths worldwide, with its treatment complicated by challenges such as high recurrence rates, severe side effects, and limited effectiveness of current therapies. Herbal medicine (HM) has emerged as an adjunct to palliative chemotherapy (PC), potentially improving tumor response and reducing side effects. This study conducted a meta-analysis to evaluate the effectiveness and safety of HM in palliative therapy for inoperable stage Ⅲ and Ⅳ AGC patients. Methods: Databases were searched until August 2023, encompassing 10 electronic databases, including PubMed, Embase, Cochrane Library, CNKI, and ScienceON. The inclusion criteria focused on randomized controlled trials (RCTs) combining herbal medicine with palliative therapy for patients with AGC. Primary outcomes assessed were tumor response rates, overall survival, adverse drug reactions (ADRs), and patients' quality of life (QoL). Results: In our analysis of 101 RCTs comparing PC alone to PC combined with HM, the meta-analysis demonstrated statistically significant improvements in overall response rate (ORR), disease control rate (DCR), survival rates, as well as a reduction in adverse drug reactions (ADRs) and an enhancement in quality of life (QoL) for patients receiving HM in combination with PC (p < 0.00001, I² = 0 %). Conclusion: The combination of HM with PC significantly enhances tumor response and survival rates while reducing overall adverse drug reactions (ADRs) and improving quality of life (QoL) in patients with stage Ⅲ and Ⅳ AGC. HMs not only improve the efficacy of PC but also help alleviate side effects, including myelosuppression, digestive symptoms, nausea, vomiting, diarrhea, liver and renal injuries, and neurotoxicity. Protocol registration: PROSPERO, CRD 42022354133.

키워드

Advanced gastric cancerHerbal medicineMeta-analysisPalliative chemotherapyDISEASE-FREE SURVIVALQUALITY-OF-LIFEDISTAL GASTRECTOMYBREAST-CANCEREFFICACYVERSIONCAPECITABINERADIOTHERAPYFREQUENCY

식별자

Scopus EID
2-s2.0-85215562178
WoS UID
001408817100001
KCI
ART003184609